4th Annual Clinical Site Partnerships in Central & Eastern Europe, to be held in Budapest, Hungary

7th-8th Septermber 2009, Budapest, Hungary.
Central & Eastern Europe continues be one of the most attractive regions globally for running clinical trials. With it's substantial pool of patients, centralized healthcare system and highly motivated investigators it still offers time, cost and quality advantages over other territories.

This event will build upon our previous meetings by examining in detail the current clinical landscape impacting clinical trials in the CEE & CIS regiondealing with longstanding regulatory obstacles, site selection and performance hurdles, approaches to ensure the quality and integrity of data and improving understanding of clinical trials amongst the region's population. Particular attention will also be given to the continuing barriers to improvements in EU member states as well as Russia, Ukraine and the Balkan regions via focused conference sessions.

NextLevel Pharma's "Clinical Site Partnerships in Central & Eastern Europe" event is the only meeting which provides the opportunity to participate in 1 on 1 partnering sessions enabling trial sponsor companies, CROs, clinical solution providers, and sites themselves to meet with one another to discuss potential partnerships.

Why attend:

  • Learn how CEE can consolidate its position as a highly productive region for clinical research.
  • Hear fresh perspectives from Ministries of Health, ethics committees, clinical research associations, patient organisations and sites as well as sponsor companies on how to improve the region's clinical research infrastructure.
  • Gain vital local knowledge and improve relationships by hearing from sites directly via presentations and partnering meetings.
  • Develop your approach to train, motivate and support clinical teams in these specific regions.
  • Case study presentations from experts with focus also given to Russia, Ukraine, Turkey and the Balkans.
  • Learn and implement the most efficient partnership model in CEE to maximise the performance of your clinical partners.
  • Partner with the leading clinical solution providers operating in CEE/CIS in our exclusive 1-on-1 partnering sessions.
  • Network and build the contacts & relationships you need at NextLevel Pharma's very popular & entertaining networking dinner.

Who will benefit:

  • Pharmaceutical & Biotechnology Organisations: Global / European / Regional / Country Heads of Clinical Operations, Clinical Development, Outsourcing, Contract Management, Risk Management, R&D Sourcing, Business Development. Project Managers, Study Managers, and Senior CRAs,
  • CROs & Clinical Solution Providers: CEOs, Business Development Directors, Product Managers, Marketing Managers and Country Managers from the region.
  • Clinical Sites: Principal Investigators, Co-Investigators, Study Coordinators, Study Nurses and others involved in clinical research.

For further information and registration, please visit:
https://www.nextlevelpharma.com/events/view/4th_annual_clinical_site_partnerships_in_central_eastern_europe

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...